Role of interleukin-6 in the pathogenesis of an avian model of Staphylococcus aureus arthritis.
To evaluate the role of interleukin-6 (IL-6) in arthritis induced by Staphylococcus aureus, a chicken model was developed for study. A total of 120 healthy broilers (8 wk old) were randomly divided into 4 groups. Two groups were injected with 0.35 mL of Staph. aureus (7.1x10(9) cfu/mL) into the right hock joints and the other 2 were injected with 0.35 mL of sterile saline into the same joints. One group of each of the 2 treatment groups was fed levofloxacin at a dose of 5 mg/kg of BW on the third day postinoculation for 4 successive days. Chicken blood samples were obtained on d 0, 1, 4, 7, 14, 21, 28, and 35 postinoculation. Chicken IL-6 (chIL-6) activities and concentrations in serum were quantified by B9 bioassay and human IL-6 ELISA, respectively. The results showed that chIL-6 activities and concentrations were reduced (P<0.05) in the serum of infected broilers treated with levofloxacin compared with birds injected only with Staph. aureus. Levofloxacin treatment had no effect on IL-6 activities and concentrations in uninfected broilers. There was a strong correlation (r=0.91) between serum chIL-6 activities by the B9 bioassay and serum IL-6 concentrations determined by the human IL-6 ELISA. We concluded that chIL-6 is involved in the progression of chicken arthritis induced by Staph. aureus, and that it contributes to disease incidence and mortality.
Zhou
Q
Q
MOA Key Laboratory Food Safety Evaluation, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, P. R. China, 430070.
Gu
C Q
CQ
Hu
X Y
XY
Wang
D H
DH
Li
X M
XM
Zhou
S Q
SQ
Cheng
G F
GF
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001170:Arthritis, Infectious / Q000188:drug therapy / Q000378:metabolism* / Q000382:microbiology / Q000473:pathology*; D002645:Chickens / Q000378:metabolism / Q000382:microbiology; D004195:Disease Models, Animal; D015850:Interleukin-6 / Q000097:blood / Q000378:metabolism*; D064704:Levofloxacin; D015242:Ofloxacin / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000378:metabolism* / Q000382:microbiology / Q000473:pathology*; D013211:Staphylococcus aureus
D000900:Anti-Bacterial Agents; D015850:Interleukin-6; D064704:Levofloxacin; D015242:Ofloxacin